These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38158924)
41. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials. Albakr RB; Sridhar VS; Cherney DZI Am J Kidney Dis; 2023 Dec; 82(6):737-742. PubMed ID: 37517546 [TBL] [Abstract][Full Text] [Related]
42. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098 [TBL] [Abstract][Full Text] [Related]
43. Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. Nistor I; De Sutter J; Drechsler C; Goldsmith D; Soler MJ; Tomson C; Wiecek A; Donciu MD; Bolignano D; Van Biesen W; Covic A Nephrol Dial Transplant; 2018 Jan; 33(1):12-22. PubMed ID: 29106631 [TBL] [Abstract][Full Text] [Related]
44. [Finerenone (Kerendia®), a new weapon against the chronic kidney disease of a patient with type 2 diabetes]. Scheen A; Delanaye P Rev Med Liege; 2023 Dec; 78(12):725-732. PubMed ID: 38095038 [TBL] [Abstract][Full Text] [Related]
45. Role of mineralocorticoid receptor antagonists in kidney diseases. Patel V; Joharapurkar A; Jain M Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798 [TBL] [Abstract][Full Text] [Related]
46. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983 [TBL] [Abstract][Full Text] [Related]
47. Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Rossing P Kidney Int Suppl (2011); 2022 Apr; 12(1):27-35. PubMed ID: 35529090 [TBL] [Abstract][Full Text] [Related]
48. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Agarwal R; Anker SD; Bakris G; Filippatos G; Pitt B; Rossing P; Ruilope L; Gebel M; Kolkhof P; Nowack C; Joseph A; Nephrol Dial Transplant; 2022 May; 37(6):1014-1023. PubMed ID: 33280027 [TBL] [Abstract][Full Text] [Related]
49. Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown. Fu EL; Kutz A; Desai RJ Kidney Int; 2023 Jan; 103(1):30-33. PubMed ID: 36603981 [TBL] [Abstract][Full Text] [Related]
50. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management. Beavers CJ Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052 [TBL] [Abstract][Full Text] [Related]
51. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)]. Santoro A; Mandreoli M G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183 [TBL] [Abstract][Full Text] [Related]
53. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS; JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567 [TBL] [Abstract][Full Text] [Related]
54. Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. D'Marco L; Puchades MJ; Gandía L; Forquet C; Giménez-Civera E; Panizo N; Reque J; Juan-García I; Bermúdez V; Gorriz JL touchREV Endocrinol; 2021 Nov; 17(2):84-87. PubMed ID: 35118452 [TBL] [Abstract][Full Text] [Related]
56. [Current options for slowing the progression of chronic kidney disease]. Tesař V Vnitr Lek; 2022; 68(7):420-424. PubMed ID: 36402565 [TBL] [Abstract][Full Text] [Related]
57. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B; Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733 [TBL] [Abstract][Full Text] [Related]
58. Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus. Rastogi A; Weir MR J Diabetes Complications; 2023 Aug; 37(8):108515. PubMed ID: 37356235 [TBL] [Abstract][Full Text] [Related]
59. Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection. Parfianowicz D; Shah S; Nguyen C; Maitz TN; Hajra A; Goel A; Sreenivasan J; Aronow WS; Vyas A; Gupta R Curr Probl Cardiol; 2022 Dec; 47(12):101386. PubMed ID: 36057315 [TBL] [Abstract][Full Text] [Related]
60. The emerging pillars of chronic kidney disease: no longer a bystander in metabolic medicine. Wonnacott A Clin Med (Lond); 2023 May; 23(3):254-258. PubMed ID: 37236791 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]